Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 350 of 360 entries
View as:

Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

Phase: N/A Priority: Normal
NCT ID: NCT00566462 Org: User:
Start: 10/31/07 End: 12/01/08 Due: 12/01/09

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02211222 Org: User:
Start: - End: 06/30/15 Due: 06/30/16

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02322021 Org: User:
Start: 11/26/14 End: 12/20/19 Due: 12/20/20

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT03208660 Org: User:
Start: 04/07/17 End: 03/15/19 Due: 03/15/20

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00688376 Org: User:
Start: 07/02/08 End: 05/26/09 Due: 05/26/10

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00388726 Org: User:
Start: 11/30/06 End: 06/30/13 Due: 06/30/14

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

Phase: N/A Priority: Normal
NCT ID: NCT00592904 Org: User:
Start: 01/31/08 End: 07/31/11 Due: 07/31/12

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Phase: N/A Priority: Normal
NCT ID: NCT01230853 Org: User:
Start: 08/31/10 End: 02/28/13 Due: 02/28/14

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01335009 Org: User:
Start: 05/16/11 End: 04/10/20 Due: 04/10/21

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Phase: N/A Priority: Normal
NCT ID: NCT05137847 Org: User:
Start: 05/24/21 End: 03/17/23 Due: 03/17/24

Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00711204 Org: User:
Start: 01/31/08 End: - Due: -

An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Flexible Bronchoscopy

Phase: N/A Priority: Normal
NCT ID: NCT00306722 Org: User:
Start: 04/30/06 End: 05/31/07 Due: 05/31/08

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT00828932 Org: User:
Start: 08/31/08 End: 12/31/08 Due: 12/31/09

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT00051012 Org: User:
Start: 09/30/95 End: 12/31/06 Due: 12/31/07

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01104155 Org: User:
Start: 02/22/10 End: 01/18/17 Due: 01/18/18

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Phase: N/A Priority: Normal
NCT ID: NCT04457687 Org: User:
Start: - End: - Due: -

Study to Assess Safety and Efficacy of AQUAVAN® Injection for Sedation During Cardiac Catheterization

Phase: N/A Priority: Normal
NCT ID: NCT00209547 Org: User:
Start: 02/29/04 End: 03/31/05 Due: 03/31/06

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02199379 Org: User:
Start: 11/30/11 End: 10/31/12 Due: 10/31/13

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03451110 Org: User:
Start: 02/05/18 End: 03/23/18 Due: 03/23/19

Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02583451 Org: User:
Start: 11/30/15 End: 02/28/17 Due: 02/28/18

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Phase: N/A Priority: Normal
NCT ID: NCT02019264 Org: User:
Start: 01/24/14 End: 05/14/18 Due: 05/14/19

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Phase: N/A Priority: Normal
NCT ID: NCT01529112 Org: User:
Start: 11/30/11 End: 06/27/15 Due: 06/27/16

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Phase: N/A Priority: Normal
NCT ID: NCT01433978 Org: User:
Start: 03/26/12 End: 09/30/13 Due: 09/30/14

A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00130169 Org: User:
Start: 01/31/06 End: 08/31/09 Due: 08/31/10

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04971733 Org: User:
Start: 06/28/21 End: 05/24/24 Due: 05/24/25